Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Engineered Fibrillar Fibronectin Networks as Three-Dimensional Tissue Scaffolds.

Jordahl S, Solorio L, Neale DB, McDermott S, Jordahl JH, Fox A, Dunlay C, Xiao A, Brown M, Wicha M, Luker GD, Lahann J.

Adv Mater. 2019 Sep 30:e1904580. doi: 10.1002/adma.201904580. [Epub ahead of print]

PMID:
31565823
2.

Short-term cellular memory tunes the signaling responses of the chemokine receptor CXCR4.

Spinosa PC, Humphries BA, Lewin Mejia D, Buschhaus JM, Linderman JJ, Luker GD, Luker KE.

Sci Signal. 2019 Jul 9;12(589). pii: eaaw4204. doi: 10.1126/scisignal.aaw4204.

PMID:
31289212
3.

The effect of mechanosensitive channel MscL expression in cancer cells on 3D confined migration.

Heureaux-Torres J, Luker KE, Haley H, Pirone M, Lee LM, Herrera Y, Luker GD, Liu AP.

APL Bioeng. 2018 Jun 8;2(3):032001. doi: 10.1063/1.5019770. eCollection 2018 Sep.

4.

Characterization, Dynamics, and Mechanism of CXCR4 Antagonists on a Constitutively Active Mutant.

Rosenberg EM Jr, Harrison RES, Tsou LK, Drucker N, Humphries B, Rajasekaran D, Luker KE, Wu CH, Song JS, Wang CJ, Murphy JW, Cheng YC, Shia KS, Luker GD, Morikis D, Lolis EJ.

Cell Chem Biol. 2019 May 16;26(5):662-673.e7. doi: 10.1016/j.chembiol.2019.01.012. Epub 2019 Feb 28.

PMID:
30827936
5.

A Caspase-3 Reporter for Fluorescence Lifetime Imaging of Single-Cell Apoptosis.

Buschhaus JM, Humphries B, Luker KE, Luker GD.

Cells. 2018 Jun 13;7(6). pii: E57. doi: 10.3390/cells7060057.

6.

Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.

Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, Shen N, Rajendran S, Cutter A, Cheng YH, Chen YT, Cong J, Spinosa PC, Yoon E, Luker KE, Luker GD.

Mol Cancer Res. 2019 May;17(5):1142-1154. doi: 10.1158/1541-7786.MCR-18-0836. Epub 2019 Feb 4.

PMID:
30718260
7.

Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors.

Shahi Thakuri P, Luker GD, Tavana H.

Transl Oncol. 2019 Mar;12(3):404-416. doi: 10.1016/j.tranon.2018.11.009. Epub 2018 Dec 14.

8.

Morphology-based prediction of cancer cell migration using an artificial neural network and a random decision forest.

Zhang Z, Chen L, Humphries B, Brien R, Wicha MS, Luker KE, Luker GD, Chen YC, Yoon E.

Integr Biol (Camb). 2018 Dec 19;10(12):758-767. doi: 10.1039/c8ib00106e.

PMID:
30420987
9.

Mammary fibroblasts remodel fibrillar collagen microstructure in a biomimetic nanocomposite hydrogel.

Liu C, Chiang B, Lewin Mejia D, Luker KE, Luker GD, Lee A.

Acta Biomater. 2019 Jan 1;83:221-232. doi: 10.1016/j.actbio.2018.11.010. Epub 2018 Nov 7.

PMID:
30414485
10.

Needs Assessment Using a Structured Prioritization Schema: An Open Letter to PACS Vendors.

Roseland ME, Kazerooni EA, Bailey JE, Luker GD, Cohan RH, Davenport MS.

J Am Coll Radiol. 2019 Feb;16(2):170-177. doi: 10.1016/j.jacr.2018.07.014. Epub 2018 Sep 13.

PMID:
30219343
11.

Monitoring implantable immunoisolation devices with intrinsic fluorescence of genipin.

Santos-Vizcaino E, Haley H, Gonzalez-Pujana A, Orive G, Hernandez RM, Luker GD, Pedraz JL.

J Biophotonics. 2019 Apr;12(4):e201800170. doi: 10.1002/jbio.201800170. Epub 2018 Sep 25.

PMID:
30058289
12.

Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone.

Hoff BA, Brisset JC, Galbán S, Van Dort M, Smith DC, Reichert ZR, Jacobson JA, Luker GD, Chenevert TL, Ross BD.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):189-199. eCollection 2018.

13.

Primary myelofibrosis evolving to an aplastic appearing marrow.

Schaefer JK, Choi SM, Luker GD, Chenevert TL, Ross BD, Talpaz M.

Clin Case Rep. 2018 May 31;6(7):1393-1395. doi: 10.1002/ccr3.1618. eCollection 2018 Jul.

14.

Enhanced Bone Metastases in Skeletally Immature Mice.

Haley HR, Shen N, Qyli T, Buschhaus JM, Pirone M, Luker KE, Luker GD.

Tomography. 2018 Jun;4(2):84-93. doi: 10.18383/j.tom.2018.00010.

15.

Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling.

Luo M, Shang L, Brooks MD, Jiagge E, Zhu Y, Buschhaus JM, Conley S, Fath MA, Davis A, Gheordunescu E, Wang Y, Harouaka R, Lozier A, Triner D, McDermott S, Merajver SD, Luker GD, Spitz DR, Wicha MS.

Cell Metab. 2018 Jul 3;28(1):69-86.e6. doi: 10.1016/j.cmet.2018.06.006.

16.

Hybrid collagen alginate hydrogel as a platform for 3D tumor spheroid invasion.

Liu C, Lewin Mejia D, Chiang B, Luker KE, Luker GD.

Acta Biomater. 2018 Jul 15;75:213-225. doi: 10.1016/j.actbio.2018.06.003. Epub 2018 Jun 5.

17.

Dual Reporter Bioluminescence Imaging with NanoLuc and Firefly Luciferase.

Gibbons AE, Luker KE, Luker GD.

Methods Mol Biol. 2018;1790:41-50. doi: 10.1007/978-1-4939-7860-1_4.

18.

3D Jet Writing: Functional Microtissues Based on Tessellated Scaffold Architectures.

Jordahl JH, Solorio L, Sun H, Ramcharan S, Teeple CB, Haley HR, Lee KJ, Eyster TW, Luker GD, Krebsbach PH, Lahann J.

Adv Mater. 2018 Apr;30(14):e1707196. doi: 10.1002/adma.201707196. Epub 2018 Feb 27.

19.

Three-dimensional tumor model mimics stromal - breast cancer cells signaling.

Ham SL, Thakuri PS, Plaster M, Li J, Luker KE, Luker GD, Tavana H.

Oncotarget. 2017 Dec 5;9(1):249-267. doi: 10.18632/oncotarget.22922. eCollection 2018 Jan 2.

20.

Functional Isolation of Tumor-Initiating Cells using Microfluidic-Based Migration Identifies Phosphatidylserine Decarboxylase as a Key Regulator.

Chen YC, Humphries B, Brien R, Gibbons AE, Chen YT, Qyli T, Haley HR, Pirone ME, Chiang B, Xiao A, Cheng YH, Luan Y, Zhang Z, Cong J, Luker KE, Luker GD, Yoon E.

Sci Rep. 2018 Jan 10;8(1):244. doi: 10.1038/s41598-017-18610-5.

21.

Fluorescence Lifetime Imaging of a Caspase-3 Apoptosis Reporter.

Buschhaus JM, Gibbons AE, Luker KE, Luker GD.

Curr Protoc Cell Biol. 2017 Dec 11;77:21.12.1-21.12.12. doi: 10.1002/cpcb.36.

22.

Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling.

Thakuri PS, Liu C, Luker GD, Tavana H.

Adv Healthc Mater. 2018 Mar;7(6):e1700980. doi: 10.1002/adhm.201700980. Epub 2017 Dec 4. Review.

23.

The CXCL12/CXCR7 signaling axis, isoforms, circadian rhythms, and tumor cellular composition dictate gradients in tissue.

Spinosa PC, Luker KE, Luker GD, Linderman JJ.

PLoS One. 2017 Nov 8;12(11):e0187357. doi: 10.1371/journal.pone.0187357. eCollection 2017.

24.

A Facile, In Vitro 384-Well Plate System to Model Disseminated Tumor Cells in the Bone Marrow Microenvironment.

Buschhaus JM, Luker KE, Luker GD.

Methods Mol Biol. 2018;1686:201-213. doi: 10.1007/978-1-4939-7371-2_15.

25.

Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168).

Van Dort ME, Galbán S, Nino CA, Hong H, Apfelbaum AA, Luker GD, Thurber GM, Atangcho L, Besirli CG, Ross BD.

ACS Med Chem Lett. 2017 Jul 24;8(8):808-813. doi: 10.1021/acsmedchemlett.7b00111. eCollection 2017 Aug 10.

26.

Dispersible oxygen microsensors map oxygen gradients in three-dimensional cell cultures.

Lesher-Pérez SC, Kim GA, Kuo CH, Leung BM, Mong S, Kojima T, Moraes C, Thouless MD, Luker GD, Takayama S.

Biomater Sci. 2017 Sep 26;5(10):2106-2113. doi: 10.1039/c7bm00119c.

27.

A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.

Galbán S, Apfelbaum AA, Espinoza C, Heist K, Haley H, Bedi K, Ljungman M, Galbán CJ, Luker GD, Dort MV, Ross BD.

Mol Cancer Ther. 2017 Nov;16(11):2340-2350. doi: 10.1158/1535-7163.MCT-17-0207. Epub 2017 Aug 3.

28.

Correction: Cell, Isoform, and Environment Factors Shape Gradients and Modulate Chemotaxis.

Chang SL, Cavnar SP, Luker KE, Takayama S, Luker GD, Linderman JJ.

PLoS One. 2017 Mar 14;12(3):e0174189. doi: 10.1371/journal.pone.0174189. eCollection 2017.

29.

Semiautomated Workflow for Clinically Streamlined Glioma Parametric Response Mapping.

Keith L, Ross BD, Galbán CJ, Luker GD, Galbán S, Zhao B, Guo X, Chenevert TL, Hoff BA.

Tomography. 2016 Dec;2(4):267-275. doi: 10.18383/j.tom.2016.00181.

30.

Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids.

Shahi Thakuri P, Ham SL, Luker GD, Tavana H.

Mol Pharm. 2016 Nov 7;13(11):3724-3735. Epub 2016 Oct 4.

PMID:
27653969
31.

Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.

Ham SL, Joshi R, Luker GD, Tavana H.

Adv Healthc Mater. 2016 Nov;5(21):2788-2798. doi: 10.1002/adhm.201600644. Epub 2016 Sep 7.

32.

In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide.

Yang D, Feng L, Dougherty CA, Luker KE, Chen D, Cauble MA, Banaszak Holl MM, Luker GD, Ross BD, Liu Z, Hong H.

Biomaterials. 2016 Oct;104:361-71. doi: 10.1016/j.biomaterials.2016.07.029. Epub 2016 Jul 26.

33.

Imaging Sensitivity of Quiescent Cancer Cells to Metabolic Perturbations in Bone Marrow Spheroids.

Cavnar SP, Xiao A, Gibbons AE, Rickelmann AD, Neely T, Luker KE, Takayama S, Luker GD.

Tomography. 2016 Jun;2(2):146-157.

34.

A Pilot Study of Quantitative MRI Parametric Response Mapping of Bone Marrow Fat for Treatment Assessment in Myelofibrosis.

Luker GD, Nguyen HM, Hoff BA, Galbán CJ, Hernando D, Chenevert TL, Talpaz M, Ross BD.

Tomography. 2016 Mar;2(1):67-78.

35.

Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.

Luker KE, Luker GD.

Methods Enzymol. 2016;570:119-29. doi: 10.1016/bs.mie.2015.08.024. Epub 2015 Nov 14.

36.

Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.

Behnam Azad B, Lisok A, Chatterjee S, Poirier JT, Pullambhatla M, Luker GD, Pomper MG, Nimmagadda S.

J Nucl Med. 2016 Jun;57(6):981-8. doi: 10.2967/jnumed.115.167932. Epub 2016 Feb 23.

37.

Fluorescence Lifetime Imaging of Apoptosis.

Xiao A, Gibbons AE, Luker KE, Luker GD.

Tomography. 2015 Dec;1(2):115-124.

38.

Potential for Early Fracture Risk Assessment in Patients with Metastatic Bone Disease using Parametric Response Mapping of CT Images.

Hoff BA, Toole M, Yablon C, Ross BD, Luker GD, VanPoznak C, Galbán CJ.

Tomography. 2015 Dec;1(2):98-104.

39.

Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells.

Stacer AC, Wang H, Fenner J, Dosch JS, Salomonnson A, Luker KE, Luker GD, Rehemtulla A, Ross BD.

Mol Imaging. 2015;14:414-28.

40.

Modeling selective elimination of quiescent cancer cells from bone marrow.

Cavnar SP, Rickelmann AD, Meguiar KF, Xiao A, Dosch J, Leung BM, Cai Lesher-Perez S, Chitta S, Luker KE, Takayama S, Luker GD.

Neoplasia. 2015 Aug;17(8):625-33. doi: 10.1016/j.neo.2015.08.001.

41.

CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.

Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN.

Mol Cancer Ther. 2015 Nov;14(11):2473-85. doi: 10.1158/1535-7163.MCT-15-0252. Epub 2015 Aug 12.

42.

CXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.

Misra AC, Luker KE, Durmaz H, Luker GD, Lahann J.

Biomacromolecules. 2015 Aug 10;16(8):2412-7. doi: 10.1021/acs.biomac.5b00653. Epub 2015 Jul 22.

43.

Phytochemicals potently inhibit migration of metastatic breast cancer cells.

Ham SL, Nasrollahi S, Shah KN, Soltisz A, Paruchuri S, Yun YH, Luker GD, Bishayee A, Tavana H.

Integr Biol (Camb). 2015 Jul;7(7):792-800. doi: 10.1039/c5ib00121h.

44.

Endothelial CXCR7 regulates breast cancer metastasis.

Stacer AC, Fenner J, Cavnar SP, Xiao A, Zhao S, Chang SL, Salomonnson A, Luker KE, Luker GD.

Oncogene. 2016 Mar 31;35(13):1716-24. doi: 10.1038/onc.2015.236. Epub 2015 Jun 29.

45.

Comparative study reveals better far-red fluorescent protein for whole body imaging.

Luker KE, Pata P, Shemiakina II, Pereverzeva A, Stacer AC, Shcherbo DS, Pletnev VZ, Skolnaja M, Lukyanov KA, Luker GD, Pata I, Chudakov DM.

Sci Rep. 2015 Jun 2;5:10332. doi: 10.1038/srep10332.

46.

Cell, isoform, and environment factors shape gradients and modulate chemotaxis.

Chang SL, Cavnar SP, Takayama S, Luker GD, Linderman JJ.

PLoS One. 2015 Apr 24;10(4):e0123450. doi: 10.1371/journal.pone.0123450. eCollection 2015. Erratum in: PLoS One. 2017 Mar 14;12 (3):e0174189.

47.

Microscale 3D collagen cell culture assays in conventional flat-bottom 384-well plates.

Leung BM, Moraes C, Cavnar SP, Luker KE, Luker GD, Takayama S.

J Lab Autom. 2015 Apr;20(2):138-45. doi: 10.1177/2211068214563793. Epub 2014 Dec 15.

48.

Surface-templated hydrogel patterns prompt matrix-dependent migration of breast cancer cells towards chemokine-secreting cells.

Kojima T, Moraes C, Cavnar SP, Luker GD, Takayama S.

Acta Biomater. 2015 Feb;13:68-77. doi: 10.1016/j.actbio.2014.11.033. Epub 2014 Nov 24.

49.

High Throughput, Polymeric Aqueous Two-Phase Printing of Tumor Spheroids.

Atefi E, Lemmo S, Fyffe D, Luker GD, Tavana H.

Adv Funct Mater. 2014 Nov 5;24(41):6509-6515.

50.

Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D Culture.

Lemmo S, Atefi E, Luker GD, Tavana H.

Cell Mol Bioeng. 2014 Sep 1;7(3):344-354.

Supplemental Content

Loading ...
Support Center